N-({4-[(cyclohexyl-methyl)amino]-3-nitrophenyl}sulfonyl)-3′-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}biphenyl-4-carboxamide | 1335145-50-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-({4-[(cyclohexyl-methyl)amino]-3-nitrophenyl}sulfonyl)-3′-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}biphenyl-4-carboxamide
• 英文别名: N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulfonyl)-3'-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}biphenyl-4-carboxamide；N-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonyl-4-[3-[[(1S,2S,3S,5R)-2,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]amino]phenyl]benzamide
• CAS: 1335145-50-0
• 化学式: C₃₆H₄₄N₄O₅S
• 分子量: 644.835
• InChiKey: PRJZAERJTTUDTN-RNAXCXPESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.7
• 重原子数：
  46
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Ding Hong

  公开号：US20110237553A1

  公开（公告）日：2011-09-29

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  揭示了抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
• Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
  申请人：Abbvie Inc.

  公开号：EP2757105A1

  公开（公告）日：2014-07-23

  This invention pertains to compounds, or therapeutically acceptable salts thereof, which inhibit the activity of Bcl-2 anti-apoptotic proteins, pharmaceutical compositions containing the compounds, and compounds and compositions for use in treating diseases during which anti-apoptotic Bcl-2 proteins are expressed.

  本发明涉及抑制 Bcl-2 抗凋亡蛋白活性的化合物或其治疗上可接受的盐类、含有这些化合物的药物组合物，以及用于治疗表达抗凋亡 Bcl-2 蛋白的疾病的化合物和组合物。
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
• US8188077B2
  申请人：——

  公开号：US8188077B2

  公开（公告）日：2012-05-29
• US8343967B2
  申请人：——

  公开号：US8343967B2

  公开（公告）日：2013-01-01